bluebird bio to split into two independent companies

12 January 2021
bluebird-bio-big

USA-based biotech firm bluebird bio (Nasdaq: BLUE) has announced a plan to split into two separate companies, with one focusing on severe genetic disease and another on oncology.

The strategy, which has been approved by the board, will result in the spinout of its oncology business, with current ‘chief bluebird’, Nick Leschly, becoming chief executive.

The current president of the severe genetic diseases business, Andrew Obenshain, will continue his leadership as chief executive of bluebird bio.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology